Background: MicroRNAs (miRNAs) function as post-transcriptional gene expression regulators. Some miRNAs, including the recently discovered miR-582-3p, have been implicated in leukemogenesis. This study aimed to reveal the biological function of miR-582-3p in acute myeloid leukemia (AML), which is one of the most frequently diagnosed hematological malignancies. Methods: The expression of miR-582-3p was determined using quantitative realtime PCR in blood samples from leukemia patients and in cell lines. Cell proliferation and cell cycle distribution were analyzed using the CCK-8, colony formation and flow cytometry assays. The target gene of miR-582-3p was verified using a dual-luciferase reporter assay. The G2/M phase arrest-related molecule contents were measured using western blotting analysis. Results: We found miR-582-3p was significantly downregulated in the blood samples from leukemia patients and in the cell lines. MiR-582-3p overexpression significantly impaired cell proliferation and induced G2/M cell cycle arrest in THP-1 cells. Furthermore, cyclin B2 (CCNB2) was confirmed as a target gene of miR-582-3p and found to be negatively regulated by miR-582-3p overexpression. More importantly, CCNB2 knockdown showed suppressive effects on cell proliferation and cell cycle progression similar to those caused by miR-582-3p overexpression. The inhibitory effects of miR-582-3p overexpression on cell proliferation and cell cycle progression were abrogated by CCNB2 transfection. Conclusion: These findings indicate new functions and mechanisms for miR-582-3p in AML development. Further study could clarify if miR-582-3p and CCNB2 are potential therapeutic targets for the treatment of AML.
A deeper understanding of leukemogenesis may provide new starting points for novel therapy development.
MicroRNAs (miRNAs) are small (20-23 nucleotides) non-coding RNA molecules involved in the regulation of mRNA stability and translational efficiency [4] . Their mechanism of action has been intensively investigated through complementary binding to recognition elements in the 3′ untranslated regions (3′-UTRs) of their target mRNAs [5] . Many studies have shown that dysregulated miRNAs are often associated with cancer pathobiology and clinical manifestations [6] . The recently discovered miR-582-3p has been reported to be expressed at low levels in high-grade bladder cancer [7] and it targets AXIN2, DKK3 and SFRP1 to maintain the stem cell properties of lung cancer [8] . Interestingly, Oliveira et al. [9] found that downregulation of miR-582-3p is likely to occur in mixed lineage leukemia-rearranged (MLL-rearranged) leukemia. However, the biological function of miR-582-3p in leukemia has not yet been clarified. Cyclin B2, encoded by CCNB2 gene, participates in pathophysiological processes as a regulator of cell cycle G2/M transition, centrosome separation and bipolar spindle formation [10, 11] . CCNB2 amplification has been shown in human pituitary adenomas as well as lung and colorectal adenocarcinomas [12] . In gastric cancer, CCNB2 levels correlate with ISL1 levels, with in vivo experiments showing that CCNB2 greatly contributes to carcinogenesis [13] . When investigating karyopherin subunit-α 2 profiles in hepatocellular carcinoma, Gao et al. [14] revealed that CCNB2 and CDK1 mediate cell cycle activation. Elevated CCNB2 protein levels seem to be associated with poor clinical prognosis of breast cancer [15] .
In this study, we determined the miR-582-3p expression pattern in blood samples from leukemia patients and in cell lines representing three cancer types: AML, T-cell acute lymphoblastic leukemia (T-cell ALL) and chronic myeloid leukemia (CML). We also investigated the impact of miR-582-3p on cell proliferation and cell cycle progression, as well as the association between miR-582-3p and CCNB2 during the pathological processes underlying leukemia.
Materials and methods

Patient samples
A total of 60 plasma samples were collected from patients with newly diagnosed AML (n = 20; median age 48 years; range 18-59 years; 12 female, 8 male), T-cell ALL (n = 20; median age 45 years; range 21-64 years; 6 female, 14 male), and CML (n = 20; median age 52 years; range 25-67 years; 9 female, 11 male). Diagnostic confirmation was performed using bone marrow aspiration and biopsy at The First Hospital of Hunan University of Chinese Medicine according to the guidelines of the World Health Organization (WHO). In addition, 20 healthy volunteers were enrolled (age range 43-64 years; 6 female, 14 male) to serve as the control group. Subjects with chronic diseases or any other type of malignancy were excluded from the experimental and control groups. Prior to participation, the patients had received no chemotherapy or radiotherapy. All subjects provided written informed consent for the use of their blood samples in this study. This study protocol was approved by our local ethics committee.
The fresh blood samples were drawn on EDTA from an antecubital vein in patients or healthy control subjects using standard percutaneous venipuncture. Cell-free plasma was obtained in a 2-step centrifugation protocol (3000 rpm for 10 min and 5000 rpm for 5 min, all at 4°C) to obtain cell-free plasma. Sodium citrate was added as an anticoagulant and then the cell-free plasma was frozen at − 80°C for further analysis.
Cell culture
Cells of the cell lines HS-5 (normal) and THP-1 (AML), Molt-4 (T-cell ALL) and K562 (CML) were obtained from the American Type Culture Collection (ATCC). They were cultured in RPMI-1640 medium with 10% heat-inactivated fetal bovine serum (FBS; Gibco) and maintained in humidified atmosphere containing 5% CO 2 at 37°C.
RNA extraction and quantitative real-time PCR
Total miRNA and RNA were extracted from plasma and cells with different treatments using the RNeasy Mini Kit (Qiagen) and TRIzol reagent (Invitrogen) according to the manufacturers' instructions. Reverse transcription reactions were performed using the miRNA Reverse Transcription Kit (Applied Biosystems) for miR-582-3p and M-MLV Reverse Transcriptase (Promega Corporation) for CCNB2. The conditions for the quantitative real-time PCR were: 92°C for 10 min, followed by 40 cycles at 92°C for 10 s and 60°C for 1 min. Quantiations of miR-582-3p and CCNB2 were carried out in triplicate using TaqMan MicroRNA assay and SYBR Green Master Mix Kits (TaKaRa) on an ABI7000 sequence detector (Applied Biosystems) with the primers: miR-582-3p forward: 5′-GCACACATTGAAGAGGACAGAC-3′ and reverse: 5′-TATTGAAGGG GGTTCTGGTG-3′; U6 snRNA forward: 5′-CTCGCTTCGGCAGCACA-3′ and reverse: 5′-AACGCTTCACGAATTTGCGT-3′; CCNB2 forward: 5′-AGTGACTAAT GGCTCTGTGATGGC-3′ and reverse: 5′-TGACGGAAGTGGTTACCTGGAAG-3′; GAPDH forward: 5′-TCAACGACCACTTTGTCAAGCTCA-3′ and reverse: 5′-GCTGGTGGTCCAGGGGTCTTACT-3′.
Data were analyzed using the 2 −ΔΔCt method. The expression levels of miR-582-3p
and CCNB2 were respectively normalized to those for U6 snRNA and GAPDH.
Cell transfection
The synthetic miR-582-3p mimics (5′-UAACUGGUUGAACAACUGAACCAA-3′), negative control (miR-NC; 5′-UCACAACCUCCUAGAAAGAGUAGA-3′), CCNB2 siRNA (siCCNB2: 5′-AGTATGTAAGCAAACTCGAGT-3′) and siNC (5′-UUCUCC GAACGUGUCACGUTT-3′) were obtained from GenePharma. The pcDNA3.1-CCNB2 and pcDNA3.1 control were purchased from Ribobio.
For cell transfection, THP-1 cells were plated in 6-well plates at a density of 5 × 10 5 cells/well and incubated for 24 h. The miR-582-3p mimics, miR-NC, siCCNB2 or siNC, and pcDNA3.1-CCNB2 or pcDNA3.1 were transfected into the cells using Lipofectamine 2000 (Invitrogen) in accordance with the manufacturer's instructions. At 48 h after transfection, the cells were collected for further investigation.
Cell proliferation assay
Cell proliferation was evaluated using a Cell Counting kit-8 (CCK-8, Beyotime Institute of Biotechnology). THP-1 cells were seeded into 96-well plates at a density of 3000 cells per well with culture medium in triplicate. Then, 10 μl CCK-8 was added to each well and the mixture was incubated for 3 h at 37°C. At indicated times (0, 24, 48, 72 and 96 h), the optical density was measured at 450 nm using a microplate reader (Molecular Devices). All the experiments were independently repeated at least three times.
Colony formation assay
After 48 h transfection, THP-1 cells were seeded on six-well culture plates at 500 cells per well in triplicate and cultured for 14 consecutive days at 37°C in an atmosphere with 5% CO 2 . The naturally formed colonies (> 50 cells per colony) were fixed with acetic acid-methanol and stained with 1% crystal violet (Sigma-Aldrich), followed by manual counting under an inverted microscope (Nikon).
Flow cytometry analysis
After 48 h transfection, THP-1 cells were harvested using trypsin, washed twice with phosphate-buffered saline (PBS), and fixed in 75% ethanol overnight at 4°C. The cell pellets were then washed three times with PBS and incubated with 20 μg/ml RNase A at room temperature, followed by staining with 500 μg/ml PI (BD Biosciences) for 30 min in the dark. The DNA content was determined using a FACSCalibur flow cytometer (BD Biosciences) with ModFit 2.0 software. All experiments were independently repeated at least three times.
Bioinformatic prediction
Potential targets of miR-582-3p were searched using multiple prediction tools, including the TargetScan software (http://www.targetscan.org) and MiRanda (http://www. microrna.org) and PicTar (pictar.mdc-berlin.de) databases. These predict conserved miRNA binding sites by comparing seed sequence alignments (bases 2-8 of the miRNA).
Luciferase reporter assay
The luciferase reporter assay was performed to verify that CCNB2 is a target of miR-582-3p in THP-1 cells. A wild-type 3′-UTR fragment of human CCNB2 mRNA (ACCAGUU) containing a putative miR-582-3p-binding site was cloned into the psiCHECK2 vector (Promega Corporation). This was named WT-CCNB2-3′-UTR luciferase vector. The mutation of the 3′-UTR fragment of human CCNB2 mRNA was constructed using the QuikChange mutagenesis kit (Agilent Technologies) and also cloned into the psiCHECK2 vector to construct MUT-CCNB2-3′-UTR luciferase vector. For the luciferase assay, THP-1 cells (1 × 10 5 cells/well) were cultured in 48-well plates in triplicate and then co-transfected with WT-CCNB2-3′-UTR or MUT-CCNB2-3′-UTR luciferase vector and miR-582-3p mimics or miR-NC using Lipofectamine 2000 for 48 h, followed by luciferase activity detection with a Dual-Luciferase Reporter Assay kit (Promega Corporation).
Western blot analysis
Proteins from transfected cells were extracted using RIPA buffer (Pierce), followed by protein quantification using a BCA assay kit (Beyotime Institute of Biotechnology). Equal amounts of protein (30 μg) were separated via 12% SDS-PAGE and transferred onto nitrocellulose membranes (Millipore). Then membranes were blocked in 5% nonfat milk in PBS-Tween-20 for 1 h at room temperature, then incubated with primary antibodies against cyclin B2 (1:1000, ab185622, Abcam), CDK1 (1:1000, ab47594, Abcam), cyclin B1 (1:1000, ab32053, Abcam), P21 (1:1000, ab188224, Abcam) and GAPDH (1:500,000, #10494-1-AP, ProteinTech) overnight at 4°C. After two washes in PBS, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Abcam) for 2 h at room temperature. The protein signals of the membranes were detected using ECL Plus Detection kit (Pierce). The protein expression was quantified using Image-Pro Plus 6.0 software.
Statistical analysis
All data were analyzed with GraphPad Prism 6.0 (GraphPad Software) and expressed as the means ± SD of three independent experiments. The differences between two groups were evaluated using unpaired two-tailed Student's t-tests. Differences for multiple comparisons were subjected to one-way analysis of variance followed by Dunnett's test. A p value of less than 0.05 was considered to be statistically significant.
Results
MiR-582-3p was downregulated in AML blood samples and cells
To explore the role of miR-582-3p in AML, we first analyzed the expression of miR-582-3p in blood samples from leukemia patients (AML, T-cell ALL and CML) using quantitative real-time PCR. The miR-582-3p levels in the leukemia patients' samples were significantly lower than those in the healthy control samples ( Fig. 1a ; p < 0.001). Notably, the blood samples from patients with AML seemed to have the lowest miR-582-3p expression.
The expressions of miR-582-3p in leukemia cell lines (THP-1, Molt-4 and K562) were also determined and compared with those in normal HS-5 cells. As expected, the expressions of miR-582-3p were remarkably lower in all leukemia cell lines ( Fig. 1b; p < 0.01, p < 0.001). Again, AML cell line THP-1 expressed the lowest miR-582-3p 
level, so it was selected for the in vitro experiments. These results show that miR-582-3p expression is obviously decreased in AML samples and cells.
MiR-582-3p inhibited cell proliferation and induced cell cycle arrest in AML cells
Because miR-582-3p is downregulated in AML, we speculated that miR-582-3p might be a tumor suppressor in AML cells. We constructed an in vitro miR-582-3p-overexpressing THP-1 cell model to investigate the function of miR-582-3p in AML. Transfection with miR-582-3p mimics significantly increased miR-582-3p expression compared with the level after miR-NC transfection ( Fig. 2a ; p < 0.001). The CCK8 assay showed obvious suppression of THP-1 cell growth after miR-582-3p overexpression ( Fig. 2b ; p < 0.001).
The colony formation assay revealed that upregulation of miR-582-3p decreased the number of colonies formed when compared with the miR-NC group in THP-1 cells ( Fig. 2c ; p < 0.01). We also used flow cytometry to analyze cell cycle progression in THP-1 cells. The percentage of cells in G2/M phase (15.9 ± 0.2% vs. 20.1% ± 0.3%; p < 0.001) increased and the percentages in G0/G1 phase (53.6 ± 0.4% vs. 51.9 ± 0.2%; p < 0.05) and S phase (30.5 ± 0.5% vs. 28.0 ± 0.2%; p < 0.01) decreased in the miR-582-3p mimics group compared with miR-NC group in THP-1 cells (Fig. 2d) . This indicates that miR-582-3p could induce G2/M cell cycle arrest in AML cells.
MiR-582-3p directly targeted CCNB2 in AML cells
To explore the potential molecular mechanism of miR-582-3p-mediated cell cycle arrest in AML cells, we predicted potential targets using three different commonly used miRNA target prediction algorithms. More than 300 genes were potential targets of miR-582-3p. Among those candidates, we focused on CCNB2, which is associated with cell cycle regulation. The binding sites of CCNB2 and miR-582-3p are shown in Fig. 3a .
A dual-luciferase reporter assay was then employed to further determine whether miR-582-3p could directly bind to the 3′-UTR of CCNB2 mRNA. The results suggest that miR-582-3p dramatically inhibits luciferase activity of the wild-type CCNB2 3′-UTR reporter plasmid but not that of the mutant type in THP-1 cells (Fig. 3b , p < 0.01). Western blotting showed an obvious decrease in the cyclin B2 protein level in cells transfected with miR-582-3p mimics compared to those with the miR-NC (Fig. 3c, p < 0.001) .
In addition, we analyzed the expression of CCNB2 in blood samples from AML patients and cell lines. The expression of CCNB2 mRNA was significantly higher in AML patients than that in healthy controls (Fig. 3d) . Consistently, the protein levels of cyclin B2 were all higher in the three leukemia cell lines (THP-1, Molt-4 and K562), than in the normal HS-5 cells (Fig. 3e) . The AML cell line THP-1 was selected for further analysis. These results show that miR-582-3p directly targets CCNB2 in AML cells.
Upregulation of miR-582-3p induced cell proliferation inhibition and G2/M cell cycle arrest by targeting CCNB2
To investigate the relationship between miR-582-3p and CCNB2 in THP-1 cell proliferation and cell cycle progression, THP-1 cells were transfected with siCCNB2, siNC, miR-582-3p mimics + pcDNA3.1 or miR-582-3p mimics + pcDNA3.1-CCNB2, and then evaluated for changes in cell proliferation and cell cycle progression. As shown in Fig. 4a , the protein level of cyclin B2 was significantly downregulated by siCCNB2 (p < 0.01). However, the downregulatory impact of miR-582-3p overexpression on the protein expression of cyclin B2 was abrogated by pcDNA3.1-CCNB2 transfection (p < 0.001). Results from the CCK-8 assay (Fig.  4b) showed that CCNB2 knockdown significantly suppressed cell proliferation (p < 0.001). Notably, pcDNA3.1-CCNB2 partially reversed the inhibitory effects of miR-582-3p mimics on cell proliferation in THP-1 cells (p < 0.01).
In the cell cycle assays (Fig. 4c ), cells transfected with siCCNB2 showed significantly decreased proportions of G0/G1 (64.2% ± 0.1% vs. 60.3% ± 0.1%, p < 0.01) and S phase (19.3% ± 0.2% vs. 16.7% ± 0.2%, p < 0.01), but increased proportion of G2/M phase (16.5% ± 0.1% vs. 23.0% ± 0.3%, p < 0.001) compared with siNC group, suggesting that CCNB2 knockdown also induced G2/M phase cell cycle arrest.
More importantly, CCNB2 overexpression abrogated the inductive effects of miR-582-3p overexpression on G2/M phase cell cycle arrest in THP-1 cells, as reflected by Li et 
the elevated proportion of G0/G1 phase (52.1% ± 0.3% vs. 64.5% ± 0.2%, p < 0.01) and decreased proportion of G2/M phase (26.8% ± 0.3% vs. 14.7% ± 0.4%, p < 0.01). Therefore, we speculated that upregulation of miR-582-3p induced cell proliferation inhibition and G2/M cell cycle arrest by targeting CCNB2.
MiR-582-3p targeted CCNB2 and suppressed G2/M phase arrest-related molecules
To further explore the possible mechanisms of miR-582-3p in AML cell cycle progression, we determined the expression alterations of some cell cycle regulators associated with G2/M transition. As shown in Fig. 5 , the expression levels of CDK1 and cyclin B1 were significantly downregulated, while the protein expression of P21 was upregulated after siCCNB2 transfection (p < 0.001). Of note, pcDNA3.1-CCNB2 abrogated the downregulatory impact of miR-582-3p on the expressions of CDK1 and cyclin B1 proteins (p < 0.05) and the upregulatory impacts of miR-582-3p on P21 expression (p < 0.01). Thus, we inferred that overexpression of miR-582-3p induced G2/M cell cycle arrest by targeting CCNB2, which was accompanied by suppression of markers associated with G2-to-M transition.
Discussion
In this study, we found that the expression of miR-582-3p is downregulated in samples from leukemia patients and leukemia cell lines, especially in AML samples and THP-1 Fig. 4 Upregulation of miR-582-3p induced cell proliferation inhibition and G2/M cell cycle arrest by targeting CCNB2. THP-1 cells were transfected with siCCNB2, siNC, miR-582-3p mimics + pcDNA3.1 or miR-582-3p mimics + pcDNA3.1-CCNB2. a The protein level of cyclin B2 expression was detected using western blot. b CCK8 assay was performed to evaluate cell proliferation at the indicated times following transfection. c THP-1 cells were stained with PI and subjected to flow cytometry analysis, followed by quantification of cell cycle distribution. Data are presented as means ± SD from three independent experiments. **p < 0.01, ***p < 0.001 vs. siNC; ## p < 0.01, ### p < 0.001 vs. miR-582-3p mimics + pcDNA3.1 cells. MiR-582-3p levels are also significantly decreased in bladder cancer [7] , lung cancer [8] and Hodgkin's lymphoma [16] . By contrast, miR-582-3p is upregulated in colon cancer [17] and non-functioning pituitary adenomas [18] . It is becoming clear that miR-582-3p can function as an oncogenic or tumor-suppressive miRNA, depending on the tumor type. Next, we analyzed the effects of miR-582-3p on THP-1 cell proliferation and cell cycle progression. Gain-of-function assays demonstrated that upregulation of miR-582-3p remarkably inhibited THP-1 cell proliferation and caused cell cycle G2/M arrest. Despite the lack of reports of miR-582-3p involvement in tumor cell growth, Gu et al. showed miR-582-3p had significant roles in multiple biological processes, including signal transduction, cell differentiation, cell adhesion and cell proliferation [19] . Numerous reports suggest that unrestricted cell growth and proliferation is a unique characteristic of cancer cells involved in tumor progression, and that this is primarily ascribed to cell cycle deregulation [20] [21] [22] . Here, we found that the cell cycle G2/M phase was induced by miR-582-3p overexpression.
To further explore the molecular mechanisms underlying miR-582-3p regulation of cell cycle progression, the target genes of miR-582-3p were predicted. CCNB2 was confirmed as a target gene of miR-582-3p. It is involved in cell proliferation and cell cycle progression, as confirmed in loss-of-functional and rescue experiments. CCNB2, which is associated with the G2/M phase transition, has been demonstrated to exhibit higher expression in hepatocellular carcinoma in the transcriptome analysis by Shan et al. [23, 24] . These data indicate that miR-582-3p suppression of cell proliferation might be due to cell cycle G2/M arrest.
The eukaryotic cell division cycle is controlled by oscillations in the activities of a series of cyclin-dependent kinases (CDKs) [25] . CDKs can bind to their specific catalytic subunit cyclin and activate CDK-cyclin complexes or bind to their inhibitors to inactivate CDK-cyclin complexes [26] . As a serine/threonine kinase, CDK1 is considered the pivotal initiator of M phase [27] . G2/M phase transition is also controlled by CDK1/cyclin B1 complexes, which are activated at the end of G2 phase [28] .
A previous study revealed that the hepatocellular carcinoma cell cycle was activated due to increased CCNB2 and CDK1 [14] . We checked whether G2/M phase arrest was caused by downregulation of CCNB2 by miR-582-3p. As expected, miR-582-3p overexpression had an inhibitory effect on the protein expression of CDK1 and cyclin B1 though targeting of CCNB1.
Importantly, a strong association has already been found between G2/M arrest and cell proliferation inhibition in various cancers. Ujiki et al. [29] achieved G2/M phase arrest with apigenin treatment, suppressing pancreatic cancer cell proliferation. A reduction in cell proliferation due to G2/M arrest and apoptosis was observed in quercetin glucuronide-treated lung cancer cells [30] . Our results suggest that G2/M arrest caused by CDK1/cyclin B inactivation due to a deficiency of CCNB2 is a mechanism for miR-582-3p preventing AML cell proliferation.
Deficiency of CCNB2 caused by miR-582-3p mimics led to an upregulation of P21 in leukemia cells [31] . P21 is a CDK-cyclin inhibitor that can promote cyclin B1 degradation after DNA damage and block the activation of CDK1-cyclin B1 complexes. During the G2 phase of normal human fibroblasts, P21 expression profiles markedly increased, indicating a critical role for P21 in mitosis [32] . A previous study revealed that the cross-talk between P21 and proliferating cell nuclear antigen (PCNA) arrested the cell at G2/M [33] . G2/M arrest of normal mice enterocytes is thought to require upregulation of P21 and downregulation of cyclin B1 via a p53-independent mechanism [34] . Taking these findings together, miR-582-3p appears to play a role as tumorsuppressing miRNA in AML by targeting CCNB2. However, this still needs to be confirmed in further study.
Conclusion
Our results confirmed that miR-582-3p has lower expression in leukemia cells and blood samples from leukemia patients. MiR-582-3p attenuates AML cell proliferation by arresting cells at the G2/M phase through targeting of CCNB2. This suggests that selective cell growth inhibitors may be utilized in cancer therapy. 
